MSD Global Health Innovation Fund Research
Investment Thesis
MSD Global Health Innovation Fund (MGHIF, also known publicly as Merck GHI Fund) is the corporate venture capital arm of Merck & Co. (MSD outside the US and Canada), founded in 2010 and operating as a $600M evergreen fund. The fund is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations, with the explicit goal of improving patient care. Unlike a traditional CVC that chases financial return alone, GHI Fund frames itself as bringing "venture mentality with the benefits of a strategic investor" — it backs founders while giving them access to Merck's global commercial, clinical, and regulatory infrastructure as a platform advantage. The fund is therapeutic-and-brand-agnostic, meaning it does not restrict itself to disease areas tied to Merck's own drug pipeline, but instead prioritizes digital and data infrastructure that spans the biopharma value chain.
Sector Focus
GHI Fund organizes its thesis into four investment focus areas, all published directly on its site:
- Drug Discovery & Clinical Development — opportunities to enhance drug discovery and accelerate clinical development (e.g., Aitia's causal AI, BigHat Biosciences' antibody design, Evaxion's AI-immunology vaccine platform, Unnatural Products' macrocyclic peptide discovery, Verge Genomics' human-genomics-first drug discovery, Protillion Biosciences' protein engineering).
- Manufacturing, Supply Chain, & IT — enhancing efficiency and reliability of supply chain, manufacturing, IT and enterprise operations (e.g., AeroSafe Global's cold-chain logistics, CargoSense and Transvoyant's supply-chain visibility, Tag-N-Trac's IoT traceability, ClearDATA's HITRUST-certified healthcare cloud).
- Access to Medicine & Patient Support — improving access to the right treatment for the right patient and getting patients to outcome (e.g., Transcarent's consumer health platform, RxVantage's provider education, WellDoc's FDA-cleared diabetes intervention, Ash Wellness's at-home diagnostics).
- Real World Evidence Generation — enabling transparency in outcomes through generation of real-world evidence and insights (e.g., Datavant's health-data connectivity, TriNetX's real-world-evidence research network, Atropos Health's on-demand RWE, Prognos Health's clinical AI, Verana Health's clinical databases).
Given the breadth of AI-native diagnostics, drug discovery, and clinical operations companies in the portfolio, the fund is best classified under digital health with a substantial biotech/life-sciences tech overlay.
Stage Focus
GHI Fund invests across three structured tiers rather than a single stage band:
- Accelerators (early stage): up to $2M, up to 20% ownership, deployed through three in-house accelerator programs — MSD Digital Science Studio, MSD IDEA Studios Singapore, and MSD IDEA Studios Berlin.
- Venture Capital (Series B or Series C): typically up to $10M equity in areas aligned with Merck's business needs, up to 20% ownership.
- Growth Capital: more than $10M equity when the company is signing a multiyear, multimillion-dollar services contract with Merck, up to 30% ownership.
Check Size
Roughly $250K–$2M at the accelerator/early stage, up to $10M for the core Series B/C venture tier, and $10M+ for growth-stage/services-contract-linked deals.
Lead Tendency
Mixed. GHI Fund has led rounds outright (e.g., N-Power Medicine's 2024 Series B) and co-led alongside other institutional investors (e.g., Faro's $37.3M Series B, co-led with S32 in August 2026), but also participates as a syndicate member in rounds led by financial VCs (e.g., Turbine's February 2026 $25M Series B, led by Interactive Venture Partners).
Recent Activity
The fund is actively deploying capital in 2026. Confirmed recent rounds: N-Power Medicine's $32M Series B (September 2026, continued participation alongside new investor Labcorp Venture Fund), Faro's $37.3M Series B (August 2026, co-led with S32), and Turbine's $25M Series B (February 2026, participation alongside Interactive Venture Partners and Beiersdorf). In 2024 the fund launched MSD IDEA Studios in Singapore and Berlin, committing roughly $38M over three years to expand accelerator-stage sourcing in Asia-Pacific and Europe.
Portfolio Highlights
The current portfolio spans 40+ active companies including PathAI and PreciseDx (AI-assisted pathology), Datavant and TriNetX (health data infrastructure), Transcarent (consumer health navigation), Unite Us (coordinated social-care referral networks), Saama (AI clinical analytics), Verana Health (clinical databases), and Qure.ai (AI-powered imaging/reporting). The fund also maintains a separate published "alumni portfolio" of exited or no-longer-active investments (https://msdghifund.com/alumni), which was not fully re-verified in this pass.
Team
GHI Fund is led by founding partner Bill Taranto (President & General Partner, with the fund since its 2010 inception, 30+ years of healthcare experience including FDA/USPHS background) and a team of Managing Directors, Investment Directors, and functional leads:
- Joel Krikston — Managing Director, leads venture capital investments
- David Rubin, Ph.D. — Managing Director, founding partner, molecular biologist
- Dave Stevenson — COO & Managing Director, founding partner
- Joe Volpe — Managing Director, founding partner, also GM of Merck Health Innovation PE Fund
- Hanqing Li — Investment Director, digital health (Global Corporate Venturing "Rising Star 2025")
- Vishal Sahni — Investment Director, precision medicine and diagnostics-focused
- Mike Morgan — Principal, digital health
- Alba Zurriaga Carda — Investment Director, joined from Sanofi Ventures in late 2025
- Susie Oblak — Executive Director, Strategic Innovation Alliances
Decision Process
GHI Fund operates as a structured corporate venture partnership with multiple Managing Directors and Investment Directors evaluating and co-leading deals rather than a solo-GP model; larger growth-stage checks appear tied to Merck's own commercial/services relationship with the target company, suggesting internal business-unit alignment factors into the decision beyond the investment team alone.
Founder Preferences
The fund favors technical, data-native founding teams building infrastructure or AI-driven products that plug directly into biopharma operations (discovery, manufacturing, RWE, patient access) rather than pure consumer health apps, reflecting Merck's own strategic pull-through motivation as a CVC.
Geographic Focus
Primarily North America and Europe per the fund's own site language ("Investing globally, with a focus on North America and Europe"), with a growing Asia-Pacific presence via the 2024 Singapore IDEA Studio launch.